Abstract. Prostate cancer (PCa) survival markedly decreases with the occurrence of distant metastasis, and treatment decisions can be influenced by metastasis site, and affect patient survival outcomes. The aim of the present study was to evaluate the potential prognostic value of metastasis to specific sites and the prognostic value of prostatectomy in patients with only bone metastasis, and to determine potential risk factors for bone metastasis in prostatic adenocarcinoma using large scale clinical data. The Surveillance, Epidemiology and End Results (SEER) database (2010-2013) was queried via the SEER*Stat (version 8.3.4) program. A total of 210,730 prostatic adenocarcinoma patients were identified from the SEER database between January 2010 and December 2013. Univariate and multivariate Cox regression analysis and Kaplan-Meier curves were used for survival comparisons with corresponding 95% confidence intervals. Patients with PCa with only liver metastatic lesions had worse overall and cancer-specific survival rates compared with those patients with only bone or lung metastasis. Multivariate Cox regression analysis revealed that age <50 years, married status, T1 and T3 tumor stage according to Tumor-Node-Metastasis (TNM) staging system from the 7th AJCC cancer staging manual, and prostatectomy were associated with better overall survival and cancer-specific survival in patients with only bone metastasis. Binary logistic regression analysis revealed that unmarried status, African descent and undifferentiated histological grade were risk factors for PCa bone metastasis. Prostatic adenocarcinoma patients with only liver metastasis had worse prognostic outcomes compared with patients with other distant organ metastases. Prostatectomy improved the 3-year survival rate in stage IV PCa patients and stage IV PCa patients with only bone metastasis. These findings were based on large-scale clinical data and can provide novel perspectives for the treatment of patients with advanced prostate adenocarcinoma.
Introduction
Prostate, lung and colorectal cancer account for ~42% of all cancer types in men, and prostate cancer (PCa) accounts for almost one in five newly diagnosed cancer cases in the United States (1) . In the United States, PCa is the most common cancer in men, and PCa-specific mortality ranks second, after that of lung cancer (2) . Although four well-established risk factors have been identified, namely increased age, ethnicity, obesity and family history, other potential factors that determine the risk of developing PCa are not well known (3, 4) . Histologically, most cases of PCa are classified as acinar adenocarcinoma and have a poor prognosis (5) .
There is increasing awareness that cancer metastasis plays an important role in the survival of PCa patients. Treatment decisions for PCa patients differ according to both patient-and disease-related factors. Radical prostatectomy (RP) is the standard treatment for clinically localized PCa, and it provides adequate local control in organ-confined disease (6) . Traditionally, RP is discouraged in patients with advanced disease, owing to the increased complication rate and treatment-related morbidity (7) . In recent years, it has been suggested that prostatectomy may provide a benefit for metastatic PCa patients (8) ; however, for advanced disease with site-specific metastasis of the bone, brain, liver or lung, there is insufficient evidence to support the efficacy of prostatectomy, particularly RP which includes including total prostatectomy and cystoprostatectomy.
To the best of our knowledge, analyses of the prognostic value of organ-specific metastasis based on large population-based data for PCa are lacking. Thus, in the present study, the data pertaining to metastatic prostate adenocarcinoma patients registered in the Surveillance, Epidemiology and End Results (SEER) database was reviewed, and the prognostic outcomes were analyzed to assess the efficacy of prostatectomy among patients with bone metastasis only.
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Data collection/selection and description of participants.
The Statistical analysis. In the present study, the χ 2 test was used to compare the clinicopathological characteristics among cases with and without bone metastasis. Kaplan-Meier analysis was used to build survival curves and log-rank testing was employed for the comparison of long-term survival outcomes. The Cox proportional hazards regression model was employed to perform univariate and multivariate analyses of the hazard ratios with corresponding 95% confidence intervals (CIs) of the study variates. Associations between marital status, age at diagnosis, race, histological grade and TNM stage at diagnosis were examined by binary logistic regression. A two-tailed P-value of <0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS software 20.0 (IBM Corporation).
Results
Incidence of different metastatic sites among stage IV PCa patients. The selection criteria are shown in Fig. 1 . Among 210,730 cases identified in the SEER database, a total of 10,777 patients with stage IV prostatic adenocarcinoma between January 2010 and December 2013 were included in the present study. (Table III) . Next, Kaplan-Meier survival analysis was performed to calculate the differences in OS and CSS by the variates identified through multivariate Cox hazards regression analysis (Fig. 2) . The 3-year CSS rate of patients who received prostatectomy was 97.3%, compared with 54.3% in patients who did not undergo prostatectomy (P<0.0001). The 3-year OS rate of patients who received prostatectomy was 96.0%, whereas that of patients who did not was only 47.4% (P<0.001) (Fig. 2E ). Married status, age <50 years and radiation therapy also led to higher 3-year CSS and OS rates ( Fig. 2A , B and D). By contrast, M1 stage, bone metastasis, liver metastasis, lung metastasis and black race were associated with reduced survival in stage IV PCa patients ( Fig. 2C and F-I).
Impact of site-specific metastasis on survival outcomes.
As it was found that metastasis to different organs may induce different survival outcomes in stage IV PCa patients, Kaplan-Meier survival analysis was performed to compare OS in advanced PCa patients with metastasis to the bone, brain, liver and lung. A total of 608 patients with metastatic lesions in multiple organs were excluded, and 10,169 patients were included in the analysis. Of these patients, 52.74% had bone metastasis, 0.22% had brain metastasis, 0.42% had liver Figure 1 . Flow chart of the study, including selection and exclusion criteria. NOS, not otherwise specified; AJCC, American Joint Committee on Cancer; PCa, prostate cancer; CSS, cancer-specific survival; OS, overall survival. Table II . Univariate analysis of CSS and OS in 10,777 patients with advanced prostate cancer. (Tables V and VI) . On the other hand, 'other' race (American Indian/Alaska native and Asian/Pacific Islander), T1 stage, T3 stage and prostatectomy were regarded as 'protective' factors in stage IV patients with only bone metastasis, moreover, T2 stage was additionally regarded as a 'protective' factor for CSS in stage IV PCa patients but not OS (Tables V and VI) .
Prostatectomy is effective in improving survival outcomes in patients with advanced PCa with only bone metastasis.
Kaplan-Meier analysis was conducted using significant factors from Cox regression analysis to determine their impact on survival in patients with stage IV PCa with only bone metastasis. According to the results, married patients had better 3-year survival rates than single/unmarried patients (CSS, 51.9 vs. 46.2%; OS, 45.6 vs. 38.5%; Fig. 4A ). 'Other' race patients (American Indian/Alaska native and Asian/Pacific Islander) also had better CSS and OS than white patients (Fig. 4B ). T1 and T3 stage patients had better CSS and OS than T0 stage patients, although this difference was not statistically significant (Fig. 4C ). Radiation therapy did not significantly improve patient's survival (Fig. 4D) . Moreover, it was found that prostatectomy could potently improve the 3-year CSS and OS rates (vs. no prostatectomy; CSS, 85.1 vs. 49.0%; OS, 81.5 vs. 42.1%; Fig. 4E ). The HR of CSS in patients with T2 stage bone metastases was 0.523; suggesting that patients with stage T2 cancer had improved specific survival outcomes compared with T0 patients (Table VI) . However, as the effect of T2 stage did not significantly affect OS, it is possible that T2 stage would be a protective factor for survival outcomes in single bone metastasis PCa patients.
Discussion
The main findings of the present study were: i) Prostate adenocarcinoma patients with only liver metastasis had worse prognostic outcomes than those with only bone or only lung metastasis; ii) prostatectomy potently improved the CSS and OS of stage IV PCa patients with only bone metastasis; and iii) unmarried status, age ≥50 years, M1 stage, bone metastasis, liver metastasis and lung metastasis were risk factors for survival in patients with stage IV PCa. The Cox regression model is widely used in survival analysis with censoring data and different covariates (11) . When analyzing survival data of the patients, the HR generated by Cox regression model represents the probability of death at a particular time. The Kaplan-Meier curve can efficiently use all data, including the censored data, to estimate the time-to-event curve. Comparisons of different groups is assessed by log-rank test, which is able to estimate the long-term prognosis of patients (11) . Therefore, survival analysis of stage IV PCa patients and single bone metastasis advanced PCa patients was performed using the Cox regression model and Kaplan-Meier analysis methods.
Using COX regression models, M1 stage, bone metastasis, liver metastasis and lung metastasis were first identified to be significantly associated with impaired CSS and OS (Tables II and III) among stage IV PCa patients. Radiation therapy and prostatectomy were also identified to be effective therapeutic methods to improve patient CSS and OS in advanced PCa.
The bone was revealed to be the most common metastatic site for stage IV PCa, and patients with bone metastases had significantly impaired CSS and OS rates. Therefore, it was necessary to find risk factors that were associated with bone metastasis in stage IV PCa. Multivariate binary logistic regression analysis suggested that single/unmarried patients, black patients and patients with grade IV (undifferentiated adenocarcinoma) were more likely to have bone metastasis (Table VI) . However, T3 stage, T4 stage and N1 stage were 'protective' factors. One possible explanation for this result is that certain groups of patients were included that were diagnosed as having stage IV PCa according to the AJCC 7th edition, but did not have metastatic disease: Patients with i) any T stage, N1, M0; ii) T4,any N stage, M0; and iii) T3, N1, M0.
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As bone metastasis may potently impair survival outcomes for patients with stage IV PCa, finding effective treatment methods to improve the CSS and OS of patients with bone metastasis is necessary. Historically, RP has not been recommended for patients with advanced PCa presumed to have extra-prostatic disease; instead, patients with advanced PCa were counseled to undergo radiation therapy or hormonal therapy (12) . However, local resection of the primary site for metastatic solid tumors has been demonstrated to be helpful in various cancer types, including metastatic renal cell carcinoma, hepatocellular carcinoma, pancreatic cancer and metastatic breast cancer (13) (14) (15) (16) (17) (18) (19) (20) (21) . Culp et al (8) demonstrated that metastatic PCa patients undergoing definitive local treatment had higher 5-year OS and CSS rates than those not undergoing local therapy. For patients with PCa, there is still no consensus about the benefit of primary site surgery in the presence of metastatic disease. The current findings demonstrate that, for patients with bone metastasis, prostatectomy may significantly improve both CSS and OS (Fig. 4) . Although radiation therapy provided obvious improvements in both CSS and OS in stage IV PCa patients (Fig. 2) , the present results indicated that there was no significant improvement in CSS and OS with the administration of radiation therapy to patients with only bone metastasis (Fig. 4) .
Mechanisms underlying the survival benefit of primary tumor resection remain unknown. According to the 'self-seeding' hypothesis, cancer cells may seed distant sites, as well as the primary tumor site (22, 23) . Eliminating the primary source of the metastatic tumor cells by removing the prostate may reduce the number of circulating tumor cells (24) . Therefore, it is reasonable to believe that prostatectomy may be beneficial for patients with metastatic PCa.
Cooperberg et al (25) showed that PCa patients aged ≥50 years may show higher CAPRA scores (the CAPRA score was developed using the Cancer of the Prostate Strategic Urologic Research Endeavor registry data) (26), implying 
Bone metastasis
Multivariate analysis that older age increases the risk of metastasis in PCa patients. Similarly, in the present study, it was demonstrated that age ≥50 years was a risk factor for both CSS and OS in patients with only bone metastasis (Tables V and VI) . The current study also revealed that patients with grade IV PCa (undifferentiated) had a higher risk of bone metastases than grade I patients (Table IV) . Moreover, Brawley et al (27) suggested that mortality rates for patients with PCa are higher for black Americans than for white Americans. The findings of the current study also suggested that black patients with stage IV PCa had worse CSS and OS compared with white patients (Fig. 2) . A recent study by Guo et al (28) suggested that liver, lung or brain metastasis resulted in a poorer prognosis in prostate cancer patients diagnosed with bone metastasis (28) . By contrast, the present study assessed the effects of four specific single metastasis sites on the survival of patients with advanced PCa. Moreover, prostatectomy was identified as an effective treatment for PCa patients with single bone metastases instead of radiation therapy. Analysis of the association between disease prognosis and metastatic site may help in optimizing disease management and devising systemic therapy strategies for PCa. The current findings suggested that patients with only liver metastasis had worse CSS and OS rates compared with those with only bone or liver metastasis (Fig. 3) .
The following limitations of the present study should be considered. First, information about smoking, obesity, Gleason scores and other risk factors for PCa were not registered in the SEER database. The current analysis only evaluated prostatectomy (RP; total prostatectomy Table V . Univariate COX analysis of CSS and OS in patients with advanced prostate cancer and only bone metastasis. and cystoprostatectomy were included) for metastatic PCa patients, but specific surgical information was not included (e.g., the use of laparoscopic or robotic-assisted surgeries).
Resection of metastatic lesions can also affect the survival outcomes of patients with metastatic PCa, but such information cannot be retrieved from the SEER database. In addition, information on androgen deprivation therapy and neoadjuvant chemotherapy, are not included. The dataset used was representative only of the United States, so the applicability of the results to a wider population is uncertain. As the current study was based on patient data from 2010-2013, 5-year survival rate, which is deemed as an effective indicator for predicting the long-term prognosis of patients, was not available. Instead, 3-year survival rate was used as an indicator to estimate the prognosis of patients with advanced PCa. Studies based on updated SEER PCa data that include >5 years of records of 'specific site metastases' can provide 5 year-survival rate, as a long-term prognosis indicator, to further validate the current results. Although the prognosis of PCa patients can be changed with improvements of treatment, we still hypothesize that prostatectomy is beneficial for prognosis outcomes of patients with stage IV PCa.
In conclusion, based on the results of SEER analysis, patients with advanced prostatic adenocarcinoma with only liver metastasis have worse outcomes than those with only bone or lung metastasis. Despite the limitations of the SEER database, the current results suggest that prostatectomy confers a survival advantage in PCa patients with only bone metastasis. Table VI . Multivariate COX analysis of CSS and OS in patients with stage IV prostate cancer with only bone metastasis. and statistical analysis. YD and WAR wrote the article. CW funded the study. All authors read and approved the final manuscript.
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